Listened to the entire concall. Notes below(I may have misheard some parts. Not a sebi advisor)
Risn pharma did a milestone payment of 26 crores.
ROW(regulated markets in Canada, Europe, Australia) and Api growth will continue next quarter. Chinese supply is back in the market for api but since alembic caters to premium no pricing pressure for alembic yet. Under invested in api right now… 400 to 500 crores capex in api and injectables next 2 years and approx 300 crores in maintenance capex. 6 products to be launched in Q4.
Domestic branded growth in specialty was good and will continue. Cough and cold should slowly get back to normalising in Q4 due to the vaccine. Growth in India was due to older brands. New brands will take a few years to pick up. Trade practices set pre pandemic helped. Post covid we ll now see even more growth in India since covid was a hindrance to it.
Regards USA, last 8 quarters provided loads of opportunities which are now slowing down. Sartans slowing down is the main factor and won’t reach previous quarter highs for some time. Launches from last quarter only contributed for few weeks end of December. No short term guidance but did mention usa should be similar to Q3 but very bullish on Us market over 2 to 3 years(400 to 500 million USD by FY 24)
Debt of 600 crores will be paid off by FY 23(ncds) ie 100 crores in FY 22 and rest in FY 23
R&D to come down to 9 percent or so over the next few years